STAT
OCTOBER 10, 2023
A growing number of AI tools are being used to predict everything from sepsis to strokes, with the hope of accelerating the delivery of life-saving care. But over time, new research suggests, these predictive models can become a victim of their own success — sending their performance into a nosedive and generating inaccurate, potentially harmful results.
PharmaVoice
OCTOBER 10, 2023
A study aimed at helping astronauts decrease bone loss could open the door to novel osteoporosis meds.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
OCTOBER 10, 2023
LONDON — In this case, it was neither the chicken nor the egg that came first. Rather, it started with some specially engineered cells in a lab. The chicken cells had had their genomes edited, not to correct a faulty mutation, but in an effort to blunt the bird flu virus. The chickens that were bred from those cells were designed to be resistant to the infection.
PharmaVoice
OCTOBER 10, 2023
A life sciences exec at Google Cloud talks about the future and fears for using AI in pharma.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
STAT
OCTOBER 10, 2023
Gina Calvanese got laid off from Jounce Therapeutics, a struggling Cambridge biotech, in April but landed a higher-paying, six-figure administrative job at a Boston drugmaker within days. Dwight Morrow was let go by Rubius Therapeutics five months before it shut down in February. But the veteran scientist quickly moved to a small startup and then got a high-ranking job at Moderna, one of the state’s biggest biotechs, all without leaving Cambridge.
BioPharma Dive
OCTOBER 10, 2023
There have been few bigger-ticket acquisitions recently. But a string of deals announced in early October may affirm the forecasts of analysts who expect M&A to tick up in the coming months.
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
Pharma Times
OCTOBER 10, 2023
The scheme will help ten projects establish research and innovation clusters - News - PharmaTimes
STAT
OCTOBER 10, 2023
One of the first items on Laurie Glimcher’s agenda after becoming CEO of the renowned Dana-Farber Cancer Institute was to build a freestanding cancer hospital in Boston. The most obvious partner would be Mass General Brigham, the large, not-for-profit system that operates the Boston hospital where Dana-Farber’s doctors currently treat cancer patients.
BioPharma Dive
OCTOBER 10, 2023
The pharma plans for the new Berkeley facility to produce clinical, and potentially commercial, supplies of a Parkinson’s disease cell therapy being tested by its subsidiary BlueRock.
STAT
OCTOBER 10, 2023
When asked where he’s from, Casey Warford often waffles. He was born in San Antonio, but raised in Georgia, and then moved back to Texas for college. It’s a little complicated because all that time Warford was dealing with a complex medical condition. The oldest of three children and a couple of close cousins, Warford was a quiet, sleepy baby.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
European Pharmaceutical Review
OCTOBER 10, 2023
Schneider Electric, a leader in digital transformation, energy management and automation, has announced the speaker lineup for its exclusive event, Life Sciences Innovation Day – Accelerating Digital Transformation Ambition. Set at the world-renowned Silverstone F1 Racetrack on 18 October 2023, it promises to be a day of immersive insights and top rate networking.
STAT
OCTOBER 10, 2023
Akero Therapeutics said Tuesday that an experimental medicine failed to show a significant benefit for patients with cirrhosis caused by NASH, the most advanced and life-threatening stage of the fatty liver disease. While the study’s primary goal of improving liver fibrosis, or scarring, was not achieved, the Akero drug, called efruxifermin, outperformed placebo by 10 percentage points.
Outsourcing Pharma
OCTOBER 10, 2023
Complete clinical trials solution company, Hawthorne Effect, announced today (October 10) announced it had successfully recruited more than 1,000 patients in 48 states plus Hawaii for a study to qualify the prevalence of valvular heart disease (VHD).
STAT
OCTOBER 10, 2023
Sana Biotechnology, a startup that just a couple of years ago raised over $1 billion off a grand plan to create a portfolio of powerful medicines, said Tuesday it would lay off nearly a third of its employees and de-prioritize one of its most ambitious programs as it looks to save money. The layoffs are Sana’s second round of cuts in less than a year.
Pharma Times
OCTOBER 10, 2023
Researchers focused on four of the most common heart conditions in the UK - News - PharmaTimes
STAT
OCTOBER 10, 2023
This article is part of a partnership between First Opinion and Tradeoffs, a podcast exploring our confusing, costly, and often counterintuitive health care system. To learn more about how the high price of this new wave of weight loss drugs is causing employers to confront their attitudes about obesity, listen to a deeper dive from Tradeoffs, and subscribe to never miss an episode.
PioneerRx
OCTOBER 10, 2023
The healthcare industry is always evolving. New medications and solutions are constantly being developed to optimize your patient’s health in new and innovative.
STAT
OCTOBER 10, 2023
My sister has a fantasy about our old age: She imagines that the seven siblings in our family will be living together again, in a house somewhere. Five will be wandering around in bathrobes, lost to dementia. The other two, their minds intact, will look after the lost ones. In this whimsical scenario, for some reason I am one of the two who stay lucid and do the caretaking.
Pharmaceutical Technology
OCTOBER 10, 2023
In a two-part column, F. Randy Vogenberg delves into why it is important to address emerging challenges in the employer-based US commercial insurance landscape.
STAT
OCTOBER 10, 2023
You’re reading the web edition of D.C. Diagnosis. Sign up here to receive this newsletter in your inbox on Tuesdays and Thursdays. What RFK’s new lane means Robert F. Kennedy is officially running for president as an independent. In a Monday afternoon Philadelphia rally, the Kennedy family scion harkened back to the Declaration of Independence and “the one other president who did not have a political party” (George Washington), promising to take on D.C. in
pharmaphorum
OCTOBER 10, 2023
Economist Impact’s Future of Health Europe summit: Building a sustainable, inclusive, and digital health system Mike.
STAT
OCTOBER 10, 2023
You’re reading the web edition of Health Care Inc., STAT’s weekly newsletter following the flow of money through the health care system. Sign up here to get it in your inbox. The latest with the Kaiser Permanente strike Kaiser Permanente health care workers who went on strike last week notified Kaiser yesterday of future strike plans, my colleague Brittany Trang reports.
European Pharmaceutical Review
OCTOBER 10, 2023
The Janssen Pharmaceutical Companies of Johnson & Johnson has revealed that according to new safety data, SPRAVATO ® (esketamine nasal spray [NS]) has demonstrated superior efficacy compared to quetiapine extended-release (Quetiapine XR) for treatment-resistant depression (TRD). This treatment is an antagonist of the N-methyl-D-aspartate (NMDA) glutamate receptor.
STAT
OCTOBER 10, 2023
Hello, everyone, and nice to see you again. We have returned from an extended weekend respite, which came about thanks to a holiday on this side of the pond. Now, of course, we have returned to the usual routine of digging for interesting items, online calls, and deadlines. This requires a cup or three of stimulation. Our choice today is pistachio creme.
cureatr
OCTOBER 10, 2023
The Centers for Medicare & Medicaid Services (CMS) is expected to propose rule changes for Medicare Part D sponsors that will likely require health plans to review and revise their strategies for their medication therapy management ( MTM) programs and delivery of MTM services. Plan sponsors should be particularly attuned to potential changes to requirements governing comprehensive medication review (CMR), especially when such changes coincide with a rapidly growing population of eligible mem
STAT
OCTOBER 10, 2023
You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how tech is transforming the life sciences. Sign up to get it delivered in your inbox every Tuesday and Thursday. How doctors and nurses shape Google’s AI At the HLTH conference, I sat down with a suite of Google’s top health execs including chief clinical officer Michael Howell , who leads a team of doctors and nurses who co-develop health products across the c
Pharmaceutical Technology
OCTOBER 10, 2023
The Gates Foundation is providing $40m in funding to advance the accessibility of Quantoom Biosciences' affordable mRNA vaccine platform.
STAT
OCTOBER 10, 2023
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hope you had a reflective Indigenous Peoples Day. Today, we talk about the implications of Bristol Myers Squibb acquiring Mirati Therapeutics, see a new lung cancer test from liquid biopsy player Delfi Diagnostics, and more.
Express Pharma
OCTOBER 10, 2023
In the ever-evolving landscape of oncology, small-molecule drugs are carving a significant niche in lung cancer treatment. In 2015, AstraZeneca’s Tagrisso achieved landmark approval from the FDA following the results of the Phase III AURA trial. This approval marked a significant advancement in the treatment of metastatic EGFR T790M mutation-positive non-small cell lung cancer (NSCLC).
pharmaphorum
OCTOBER 10, 2023
Embracing the challenges and opportunities of digital health Mike.
World Pharma News
OCTOBER 10, 2023
A University of Massachusetts Amherst team has demonstrated in theory that a protein antigen from a childhood vaccine can be delivered into the cells of a malignant tumor to refocus the body’s immune system against the cancer, effectively halting it and preventing its recurrence. The bacteria-based intracellular delivering (ID) system uses a non-toxic form of Salmonella that releases a drug, in this case a vaccine antigen, after it's inside a solid-tumor cancer cell.
Pharmaceutical Commerce
OCTOBER 10, 2023
Session offers insight on how to successfully implement cold chain transport.
pharmaphorum
OCTOBER 10, 2023
The digital skills you need for customer centric sales Mike.
Drug Patent Watch
OCTOBER 10, 2023
Annual Drug Patent Expirations for WEGOVY Wegovy is a drug marketed by Novo and is included in one NDA. It is available from two suppliers. There are five patents protecting… The post New patent for NOVO drug WEGOVY appeared first on DrugPatentWatch - Make Better Decisions.
pharmaphorum
OCTOBER 10, 2023
South Korea: Emerging global leader in life sciences Mike.
Expert insights. Personalized for you.
352 
Let's personalize your content